WILMINGTON, Del., Monday May 23 2005 AstraZeneca (NYSE: AZN) today announced results from a clinical study that examined the effectiveness of SEROQUEL and risperidone in improving cognitive function, such as memory and attention, in patients with schizophrenia. This study, which was presented at the annual meeting of the American Psychiatric Association (APA), showed that SEROQUEL and risperidone improved overall cognitive function and social skills performance in this patient population.¹ In addition, an analysis of a large health claims database showed that patients with schizophrenia taking atypical antipsychotics, including SEROQUEL, exhibited greater treatment compliance than those taking conventional antipsychotic treatments.²

SEROQUEL currently is approved for the treatment of acute manic episodes associated with bipolar I disorder and for the treatment of schizophrenia.

"Cognitive function and treatment compliance are important components to the successful, long-term management of schizophrenia. Specifically, patients who take medications that are effective and well tolerated, and who stick to that treatment, are more likely to manage their illness successfully," said Philip Harvey, Ph.D., Department of Psychiatry, Mount Sinai School of Medicine. "The results of these studies reconfirm the tolerability of SEROQUEL, as measured by treatment adherence, and its ability to improve cognitive function in patients with schizophrenia."

Cognitive Function
For patients with schizophrenia, cognitive functioning often is impaired, which can be a significant barrier to long-term recovery.¹ To date, few studies have directly compared atypical antipsychotics for the treatment of cognitive function.¹

Data presented today, drawn from an 8-week, double-blind, flexible-dose, parallel study of 673 schizophrenia patients randomized to treatment with SEROQUEL (mean modal dose of 525 mg
'"/>


23-May-2005

Page: 1 2 3 4
Related medicine news :

1. Cognitive therapy can reduce post-traumatic stress in survivors of terrorist attacks
2. High BMI Tied to Poor Cognitive Function in Middle-Aged Adults
3. Cognitive behavioral therapy appears more effective than sleep medication for treating insomnia
4. Cognitive impairment appears to be common in ALS patients
5. Cognitive therapy reduces repeat suicide attempts by 50 percent
6. Cognitive therapy effective in preventing repeat suicide attempts
7. Cognitive therapy works as well as antidepressants, but with lasting effect after therapy ends
8. New treatment boosts muscle function in myasthenia gravis
9. Penn study finds pro-death proteins required to regulate healthy immune function
10. Journal Sleep: Longer CPAP use at night can normalize ones daytime functioning
11. Human stem cell treatment restores motor function in paralyzed rats